

# Psychopharmacology

## And Substance Abuse News

Summer 2006



DIVISION 28

AMERICAN PSYCHOLOGICAL ASSOCIATION

### FROM THE PRESIDENT'S DESK

—Alan J. Budney

The APA Division of Psychopharmacology and Substance Abuse is now 40 years old. We were initially voted into the APA as the *Division of Behavioral Pharmacology* in 1966 with Murray Jarvik serving as our first President. What I find most amazing is that our Division's second President, Vic Laties, continues to serve the Division in his new found role as co-administrator of our Web site. Somewhere between 1968 and 1973, we became the *Division of Psychopharmacology*, and then in 1990 we renamed ourselves the *Division of Psychopharmacology and Substance Abuse*. These historical tidbits were gleaned from the archives of our Division newsletters, found on our Web site ([www.apa.org/divisions/div28/newsletter.html](http://www.apa.org/divisions/div28/newsletter.html)) thanks to Ron Wood's hard work over the past years.

As I began my term as President of Division 28, I embarked on a review of our history to provide some guidance and inspiration as we look forward. In so doing, I quickly realized, once again, the enormous value of looking backwards when one ponders future endeavors. In this, my initial newsletter column, I share glimpses of the past with hopes that they might inspire some to continued action in service of the Division and its mission.

In case you are wondering what our mis-

sion is, it was last published in the newsletter in 1998 when our by-laws were revised under the leadership of Nancy Ator.



The mission of this Division shall be to encourage the advancement of knowledge on the behavioral effects of psychotropic drugs and toxicants, which includes not only basic psychopharmacology research but also research into the determinants and treatment of substance abuse, the pharmacological treatment of mental illness, and other clinical uses of centrally active drugs. Three primary concerns of the Division shall be (a) disseminating research-based information on psychopharmacology and substance abuse within APA, in educational settings, and to other scientists; (b) encouraging the application of the results of psychopharmacology research to human affairs; and (c) consideration of education and policy issues pertaining to psychopharmacology, behavioral toxicology, and substance abuse.

Now back to the beginning. In the initial newsletter of the Division of Behavioral Pharmacology (*The Needle*), Murray Jarvik wrote:

*One of the main functions of our division will be to encourage research into the behavioral*

*Continued on page 2*

*effects of drugs. If certain organizations have been overenthusiastic in their expectations in the past of psychological miracles from drugs, we would like to prevent the converse reaction of rejection. One of the ways we can heighten interest in our field is to have a successful scientific program at the American Psychological Association Convention and I am appealing to members to contribute papers for the next meeting.*

Note that the chairpersons of the Division 28 symposia presented at our first APA convention included: Joe Brady, John Boren, Peter Carlton, Conan Kornetsky, and Harley Hansen. The original group that forged the *Division of Behavioral Pharmacology* was looking for a means to heighten interest and resources in a field of research that endeavored to better understand human behavior through studying the effects of drugs on behavior, which consequently offered the opportunity to better understand the effects of drugs via use of behavior. Right from the beginning, the potential for application of the knowledge gained from behavioral research on drugs was evident and acknowledged.

Unfortunately, a Division newsletter apparently was not published between 1968 and 1972 (perhaps because members thought it a waste of time to read ramblings such as mine). During that time, we became the *Division of Psychopharmacology*; why or how that came about, I am unsure but I plan to find out. I would guess the Division wanted to ensure that all psychologists conducting research related to the interplay of drugs and behavior would not be excluded, and maybe to more clearly indicate the Division's interest in the application

of drugs to modify behavior. In any event, in 1973, the newsletter reappeared under the editorial leadership of Travis Thompson. That issue of the newsletter created a "what's happening in the laboratory" section that provided brief descriptions of important accomplishments from the major behavioral pharmacology laboratories across the country. For example, it noted John Falk's report in *Science* on the use of schedule-induced polydipsia to produce physical dependence on alcohol in the rat.

In 1978, Bob Schuster, then president, headlined the newsletter with an important milestone for our field. Don MacMillan was named the Chair of the Department of Pharmacology at the University of Arkansas for Medical Sciences (which I'm proud to say is my new home). Having a behavioral pharmacologist appointed to such a position in a medical school not only acknowledged the great work of Dr. MacMillan, it demonstrated the respect and importance of the volume of work being done by our colleagues.

Linda Dykstra and Bob Balster's newsletter columns in 1989 touched on a number of issues that eerily resemble what could be topics of this year's column. Linda discussed the problems caused by animal rights activists for those conducting research with animals, in particular mentioning that Ron Wood's lab was under attack. Linda noted that we were not alone in this fight, and that the APA Science Directorate and NIDA were aggressively addressing these issues at the political level. Linda encouraged Division members to take an active role in supporting and countering this attack on our science. For those who are not aware, Division 28 leadership continues to deal with this unremitting issue. We recently took

an active role against the creation of a new APA Division of Human-Animal Studies, in part because of concerns about its potential impact on the use of animals in our scientific teaching and research (see the Council of Representatives report in this issue). Again, it was great to receive support from the Science Directorate and others when confronting this issue.

Linda also discussed the Division's efforts and impact on the pending issue of psychologists obtaining prescription privileges. Seventeen years later we remain involved with this issue, as the original training curriculum that was created with much guidance from our members, e.g. Marlyne Kilbey, Bob Balster, Frank Holloway, will be revisited by an APA task force this coming year. As with any curricula, they are a work in progress and must be reviewed periodically as research and clinical experience continue to change the discipline and practice of psychopharmacology. Our Division's role in that process will be to work to maintain the high standards of education and performance described in the current psychopharmacology curriculum. As the scientific division whose mission is to further the understanding of drugs on behavior, we should have much to say about the necessary elements of training that will ensure that psychologists can safely and effectively prescribe psychoactive medications.

In 1989, Bob Balster discussed the importance of members taking an active role to influence federal funding for our research. He reminded us how lobbying for Dr. Schuster for NIDA Director became a critical success for behavioral research on issues of drug abuse. With the current climate in

*Continued on page 3*



The President's Desk *Continued from page 2*

Washington, D.C., I would remind you again using Dr. Balster's words, "It is essential that, as scientists, educators, and concerned clinicians, we get involved in seeing that the financial resources needed for this effort are forthcoming."

This brings us into the 1990s and to our last name change. In August 1990, Bob Balster proposed that the Division change its name to *Psychopharmacology and Substance Abuse*. In his 1991 newsletter, Klaus Miczek discussed this change, indicating that a large part of our membership's interests were represented by issues of substance abuse, and as such, inclusion of this term in our name would provide a more accurate and visible representation of our interests and mission. Again, inclusiveness and integration appeared to be the theme for further advancing our science.

With this, I'll end by offering a few last comments. First, I am thankful to the membership for electing me President of Division 28. I was truly humbled by my journey through the past as it revealed a list of predecessors whose accomplishments and contributions to the field were and continue to be extraordinary. Amazingly, many of the early leaders of our Division continue to not only be some of the most productive re-

searchers, they also continue to serve the Division and represent our field of research to the greater community. I strongly encourage each of you to read through the archives of our Division. I think you will find them, as I did, personally relevant and inspiring, as you will surely note contributions associated with persons, places, or research of personal significance to you. I hope each of you will maintain heightened awareness of the issues that affect our field and thus our professional endeavors. Strive to make time for responding to these issues by providing service to our Division or taking action through other avenues. Also, please consider contributing each year to the success of our scientific program at the national APA convention. By participating in these activities, you will be showing appreciation for the time and effort devoted by former and current Division leaders that fostered a field of research and application in which we can all take pride.

Hope to see y'all in New Orleans!

Sincerely,

Alan J. Budney  
President, Division of  
Psychopharmacology  
and Substance Abuse

## FELLOWS IN DIVISION 28

### New Nominations

Each year, the Executive Committee seeks new nominations for Fellow status in Division 28. Any member who has made outstanding contributions to psychopharmacology or substance abuse is eligible. As a guide for you to determine if somebody you are thinking of nominating fits the criteria for Fellow status, here is a list that APA and our division considers when going through applications. Note that these are minimum standards under the APA Bylaws so the potential candidate must meet all of these criteria.

- 1) The receipt of a doctoral degree based in part on a psychological dissertation, or from a program primarily psychological in nature.
- 2) Prior membership as an APA member for at least one year and a member of Division 28.
- 3) Active engagement at the time of nomination in the advancement of psychology in any of its aspects (for our division, the aspect would be psychopharmacology or substance abuse).
- 4) Five years of acceptable professional experience subsequent to the granting of the doctoral degree.
- 5) Evidence of unusual and outstanding contribution or performance in the field of psychology (for our division, the field would be psychopharmacology or substance abuse).

If you wish to nominate someone for this APA honor, please send his/her curriculum vitae to me along with the person's name, current address, phone number, and e-mail.

If you have questions concerning criteria or the steps involved in the nomination process, please contact me. My contact information is listed below. I look forward to hearing from you.

Stephen Heishman, Ph.D.  
New Fellows Chair, Division 28  
NIDA Intramural Research Program  
5500 Nathan Shock Drive  
Baltimore, MD 21224

Heishman@nih.gov  
410-550-1547



# JOIN US IN NEW ORLEANS FOR THE 2006 APA CONVENTION!

This year's APA convention will be held in New Orleans, August 10–13. While parts of New Orleans suffered devastating damage as a result of Hurricane Katrina, those areas most frequented by convention attendees—the Convention Center area, French Quarter, and Garden District—were not flooded and in fact will play host to a number of large organizational meetings before our APA meeting in August.

Currently there are more than 20,000 operating hotel rooms in New Orleans. The city is back to serving the wonderful food it is known for and more than 1,000 restaurants are open for business, including the famed Emeril's NOLA, Dickie Brennan's Steakhouse, Cafe DuMonde, Dominique's, Brennan's, Arnauds, Mother's, and Galatoire's. The shops and eateries of the French Quarter are open, as is the Riverwalk Marketplace. The Audubon Zoo is now open, as well as museums such as the Ogden Museum of Southern Art, the Contemporary Arts Center, and the National D-Day Museum. The charming boutiques, galleries, and restaurants along Magazine Street are busy again, and local tours are being conducted to historic cemeteries, plantations, and other historic homes. The buggy rides and artists have also returned to Jackson Square, and there are plenty of Riverboat tours operating.

Our hope is that many of our Division 28 members will join us in New Orleans. APA has a number of programs in place to allow members

to support the continued recovery effort: APA/Habitat for Humanity building project, school supplies drive, and two evening events—a performance by Bill Cosby and one by the Preservation Hall Jazz Band—proceeds of which will go to Habitat for Humanity and the New Orleans Public Schools. More information about these and other events can be found at [www.apa.org/convention06](http://www.apa.org/convention06).

Additionally, Division 28 has a very exciting program this year with division-sponsored symposia and poster presentations on a wide range of topics of interest to researchers, clinicians, and students alike. This year's program features a special Invited Symposium, "Integration of Behavioral and Brain Sciences—Research on the Nature of Addiction," with presenters Nora Volkow, Charles Schuster, Warren Bickel, and Antoine Bechara.

We have five symposia led by Division 28 members on topics ranging from prescription opioid abuse and stimulant abuse to innovative technology-based interventions and treating drug use during pregnancy. We are also co-hosting three symposia with NIDA on topics that include environmental influences on brain development, inhibitory dysregulation, and social neuroscience.

Alan Budney will present the Presidential Address, entitled "Reflection on Marijuana Research: Scientific and Cultural Influences." Addresses will be given by this year's recipients of the Brady-Schuster (James Woods),

Wyeth Young Psychopharmacologist (Stacey Sigmon), and Outstanding Dissertation (William Stoops) awards, as well as by three of our new Division 28 fellows (Hendree Jones, Douglas Marlow, and Jane Acri).

Division 28 is co-hosting a poster session with Division 50, which will include 38 poster presentations from members of both divisions, and an Early Career Poster Session and Social Hour sponsored by NIDA and NIAAA to recognize students and young investigators.

A detailed listing of Division 28 program events is included in this issue, as well as in an e-mail that will be distributed to all Division 28 members in the upcoming weeks. Final scheduling details on these and other APA events will also be available in the APA Convention Program.

Congratulations to Division 28 Student Affiliate Kelly Dunn for being selected as the next Behavioral Neuroscience Representative for the APA Science Student Council.

DIVISION 28 THANKS THE FOLLOWING FOR THEIR SUPPORT IN 2005:

Eli Lilly and Company

•  
Friends Research  
Institute, Inc.

•  
Janssen LP

•  
MED Associates

•  
Merck

•  
Wyeth Research

Visit [www.apa.org/convention06](http://www.apa.org/convention06)  
for information about the national conference.

Visit <http://forms.apa.org/convention>  
to search for Division 28 events at the national conference.



# ANNOUNCING THE 2006 DIVISION 28 AWARD WINNERS!

—Anthony Liguori, Ph.D.  
Division 28 Awards Chair

Please join me in congratulating this year's Division 28 Award winners, all of whom will be receiving their awards and presenting lectures on the morning of August 10 at the 2006 APA Convention in New Orleans. Please reserve 8:00 to 10:00 a.m. to attend these three presentations.

The Outstanding Dissertation Award (sponsored by Friends Research Institute) winner is **William W. Stoops, Ph.D.**, of the University of Kentucky Medical Center. Dr. Stoops is a highly productive researcher, with nearly 20 peer-reviewed publications, who is already contributing extensively to the literature. His dissertation research used human drug discrimination procedures to determine whether aripiprazole (Abilify®), an atypical antipsychotic, attenuates the behavioral effects of d-amphetamine.

Craig Rush, Ph.D., will introduce Dr. Stoops' lecture and present him with an engraved plaque and a \$250 check. The title of Dr. Stoops' presentation is *The Discriminative-Stimulus Effects of d-Amphetamine: Influence of Aripiprazole Pretreatment*.

The Wyeth Young Psychopharmacologist Award winner is **Stacey C. Sigmon, Ph.D.**, of the University of Vermont. Dr. Sigmon received graduate training from Dr. Stephen Higgins at the University of Vermont, and postdoctoral training with multiple mentors at the Johns Hopkins School of Medicine. Dr. Sigmon is now the director of Vermont's largest methadone clinic for the treatment of opioid dependence. Her current research develops treatments for prescription opioid abuse and cigarette smoking

among methadone maintenance patients. She is also the Division 28 Program Chair for this year's convention.

Stephen T. Higgins, Ph.D., will introduce Dr. Sigmon's lecture and present her with an engraved plaque and a \$250 check. The title of Dr. Sigmon's presentation is *Drug Reinforcement: Using Laboratory and Clinical Models to Investigate*.

The Brady-Schuster Award (sponsored by MED Associates) winner is **James H. Woods, Ph.D.**, of the University of Michigan Medical School. Dr. Woods is an internationally renowned expert in behavioral pharmacology and the experimental analysis of behavior. He has mentored dozens of doctoral and postdoctoral students in both psychology and pharmacology. His research on benzodiazepine and opioid abuse liability

(among other topics) is among the most frequently cited in the field. Dr. Woods' service to science is reflected in his consultations to such organizations as the National Institutes of Health, the Food and Drug Administration, and the World Health Organization.

Joseph M. Moerschbaeher, Ph.D., will introduce Dr. Woods' lecture and present him with an engraved plaque and a \$500 check. The title of Dr. Woods' presentation is *Behavioral Pharmacology: Its Present and Future Prospects*.

If you are interested in being considered for one of these awards, or if you know of a deserving candidate, please e-mail Anthony Liguori at [aliguori@wfbmc.edu](mailto:aliguori@wfbmc.edu). Nominations are due at the end of the year, but it is never too early to prepare a nomination packet!

## NEW OFFICERS IN DIVISION 28.

John Grabowski, UTHSC, has agreed to take over as Council Representative. John has been President and a Council Rep in the past, and brings a wealth of experience from many areas.

Conrad Wong, University of Kentucky, will take over as liaison to the Science Directorate. Conrad has worked with the Executive Committee in the past and is enthusiastic about making things happen in this position.

### EDITORIAL POLICY

*Psychopharmacology and Substance Abuse News* is a thrice-yearly publication of Division 28. It is devoted to keeping its members informed about the activities of Division 28 and to news and comments concerning all aspects of psychopharmacology and substance abuse. Articles, comments, announcements, and advertisements should be sent to John Roll at [johnroll@wsu.edu](mailto:johnroll@wsu.edu). The deadline for the fall issue is August 15, 2006. 7/06 114067





**PROGRAM SUMMARY SHEET**  
**APA Annual Convention**

**DIVISION 28 PROGRAM SUMMARY SHEET**

EVENT, TITLE and PEOPLE	DAY/TIME	FACILITY/ROOM
Executive Committee Meeting (N): [Division 28 Executive Committee Meeting]	8/09 Wed: 6:00 PM - 7:50 PM	New Orleans Marriott Hotel Balcony I
Invited Address (S): Outstanding Dissertation Award and Wyeth Young Psychopharmacologist Award	8/10 Thu: 8:00 AM - 8:50 AM	Morial Convention Center Meeting Room 339
<p><u>Cochair</u></p> <p>Craig R. Rush, PhD</p> <p>Stephen T. Higgins, PhD</p> <p><u>Participant/1stAuthor</u></p> <p>William W. Stoops, PhD  <i>Title: Discriminative-Stimulus Effects of d-Amphetamine: Influence of Aripiprazole Pretreatment</i></p> <p>Stacey C. Sigmon, PhD  <i>Title: Drug Reinforcement: Using Laboratory and Clinical Models to Investigate</i></p>		
Invited Address (S): Brady-Schuster Award	8/10 Thu: 9:00 AM - 9:50 AM	Morial Convention Center Meeting Room 339
<p><u>Chair</u></p> <p>Joseph Moerschbaeche, PhD</p> <p><u>Participant/1stAuthor</u></p> <p>James H. Woods, PhD  <i>Title: Behavioral Pharmacology: Its Present and Future Prospects</i></p>		
Symposium (S): Behavioral Interventions for Methamphetamine Addiction---Emerging Findings With MSM	8/10 Thu: 10:00 AM - 11:50 AM	Morial Convention Center Meeting Room 350
<p><u>Chair</u></p> <p>James A. Peck, PsyD</p> <p><u>Participant/1stAuthor</u></p> <p>Martin Iguchi, PhD  <i>Title: Two-Stage Recruitment and Behavioral Interventions to Reduce HIV Risk in Drug-Using MSM</i></p> <p>James A. Peck, PsyD  <i>Title: Contingency Management for Nontreatment-Seeking, Homeless, Methamphetamine-Using MSM in Prevention Programming</i></p> <p>James A. Peck, PsyD  <i>Title: Effects of Contingency Management on Psychological Distress in Methamphetamine-Dependent MSM</i></p> <p><u>Discussant</u></p> <p>Richard A. Rawson, PhD</p>		





**PROGRAM SUMMARY SHEET**  
**APA Annual Convention**

**DIVISION 28 PROGRAM SUMMARY SHEET**

EVENT, TITLE and PEOPLE	DAY/TIME	FACILITY/ROOM
Symposium (S): Innovative Strategies to Identify and Treat Drug Use During Pregnancy	8/10 Thu: 12:00 PM - 1:50 PM	Morial Convention Center Meeting Room 340
<u>Chair</u>		
Sarah H. Heil, PhD		
<u>Participant/1stAuthor</u>		
Stephen T. Higgins, PhD		
<i>Title: Voucher-Based Incentives to Promote Smoking Cessation During Pregnancy and Postpartum</i>		
Grace Chang, MD, MPH		
<i>Title: Screening Instruments and Brief Interventions for Prenatal Alcohol Use</i>		
Hendree E. Jones, PhD		
<i>Title: Treating the Partners of Methadone-Treated Women</i>		
Michelle Tuten, MS, LCSW		
<i>Title: Reinforcement-Based Treatment for Pregnant, Drug-Dependent Women</i>		
Invited Symposium (S): Inhibitory Dysregulation and Drug Abuse	8/10 Thu: 2:00 PM - 3:50 PM	Morial Convention Center Meeting Room 336
<u>Cochair</u>		
Meyer Glantz, PhD		
Steven Grant, PhD		
<u>Participant/1stAuthor</u>		
Harriet de Wit, PhD		
<i>Title: Impulsivity as a Determinant and a Consequence of Drug Use</i>		
Hallam Hurt, MD		
<i>Title: Exploring Neurocognitive Outcome and Risk-Taking in Inner-City Youth</i>		
Martin Paulus, MD, PhD		
<i>Title: Altered Decision-Making Brain Activations Predicts Relapse in Methamphetamine Abusers</i>		
Ralph E. Tarter, PhD		
<i>Title: Neurobehavioral Disinhibition and the Liability for Substance Use Disorder</i>		
<u>Discussant</u>		
Roy F. Baumeister, PhD		





**PROGRAM SUMMARY SHEET**  
**APA Annual Convention**

**DIVISION 28 PROGRAM SUMMARY SHEET**

EVENT, TITLE and PEOPLE	DAY/TIME	FACILITY/ROOM
Invited Symposium (S): What Is the Added Value of Social Neuroscience to Drug Abuse Treatment?	8/11 Fri: 8:00 AM - 9:50 AM	Morial Convention Center Meeting Room 334
<u>Cochair</u>		
Melissa W. Racioppo, PhD		
Steven Grant, PhD		
<u>Participant/1stAuthor</u>		
Kevin Oschner, PhD		
<i>Title: Neural Mechanisms of Emotional Reappraisal: Implications for Cognitive--Behavioral Therapy for Substance Abuse</i>		
Jennifer S. Beer, PhD		
<i>Title: Orbitofrontal Cortex and Self-Monitoring</i>		
Hans Breiter, MD		
<i>Title: Dissociation of Circuitry for Utility and Attention and Their Dysfunction in Addiction and Depression</i>		
Gregory S. Berns, MD, PhD		
<i>Title: Neurobiological Correlates of Social Conformity and Independence During Mental Rotation</i>		
<u>Discussant</u>		
Diana H. Fishbein, PhD		
Samuel Ball, PhD		
Presidential Address (N): [Alan Budney]	8/11 Fri: 10:00 AM - 10:50 AM	New Orleans Marriott Hotel Mardi Gras Ballroom H
<u>Chair</u>		
Suzette M. Evans, PhD		
<u>Participant/1stAuthor</u>		
Alan J. Budney, PhD		
<i>Title: Reflection on Marijuana Research: Scientific and Cultural Influences</i>		
Business Meeting (N): [Division 28 Business Meeting]	8/11 Fri: 11:00 AM - 11:50 AM	New Orleans Marriott Hotel Mardi Gras Ballroom H
Division 28 Poster Session	8/11 Fri: 12:00 PM - 12:50 PM	Morial Convention Center Halls E and F





**PROGRAM SUMMARY SHEET**  
**APA Annual Convention**

**DIVISION 28 PROGRAM SUMMARY SHEET**

EVENT, TITLE and PEOPLE	DAY/TIME	FACILITY/ROOM
Symposium (S): Innovations in Technologies for Substance-Abuse Treatment	8/11 Fri: 2:00 PM - 3:50 PM	Morial Convention Center Meeting Room 256
<u>Chair</u>		
Jesse Dallery, PhD		
<u>Participant/1stAuthor</u>		
Warren K. Bickel, PhD <i>Title: Computerized CBT for Addiction</i>		
Lisa A. Marsch, PhD <i>Title: Computer Delivery of HIV and Hepatitis Prevention in Substance-Abuse Treatment</i>		
Kenneth Silverman, PhD <i>Title: Web-Based Therapeutic Workplace in the Treatment of Drug Addiction and Chronic Unemployment</i>		
Jesse Dallery, PhD <i>Title: Internet-Based Behavioral Treatment for Cigarette Smoking</i>		
Poster Session (N): {r}NIDA/NIAAA Early Career Poster Session and Social Hour{/r}	8/11 Fri: 4:00 PM - 6:50 PM	New Orleans Marriott Hotel Acadia Room
Invited Symposium (S): Integration of Behavioral and Brain Sciences--- Research on the Nature of Addiction	8/12 Sat: 9:00 AM - 10:50 AM	Morial Convention Center Meeting Rooms 235 and 236
<u>Chair</u>		
Alan J. Budney, PhD		
<u>Participant/1stAuthor</u>		
Nora D. Volkow, MD <i>Title: Addiction: The Neurobiology of Free Will Gone Awry</i>		
Antoine Bechara, PhD <i>Title: Decision Making, Impulse Control, and Loss of Willpower to Resist Drugs: A Neurocognitive Perspective</i>		
Warren K. Bickel, PhD <i>Title: Situating Addiction: Interaction of Brain Behavior, Development and Evolution</i>		
Charles R. Schuster, PhD <i>Title: Advancement of Addiction Science: How the Past Can Inform the Future</i>		





**PROGRAM SUMMARY SHEET**  
**APA Annual Convention**

**DIVISION 28 PROGRAM SUMMARY SHEET**

EVENT, TITLE and PEOPLE	DAY/TIME	FACILITY/ROOM
Symposium (S): Prescription Opioid Abuse---Cutting Edge Research and Policy Implications	8/12 Sat: 11:00 AM - 12:50 PM	Morial Convention Center Meeting Room 335

Chair

James P. Zacny, PhD

Participant/1stAuthor

Sandra D. Comer, PhD

*Title: Oxycodone: Laboratory Study of the Relationship Between Pain and Abuse Liability*

Christian J. Teter, <i>PharmD</i>

*Title: Characteristics Associated With Nonmedical Use of Prescription Opioids Among College Students*

Steven D. Passik, PhD

*Title: Aberrant Drug-Taking Behavior During Pain Management With Opioids: What Do We Know?*

Jack E. Henningfield, PhD

*Title: Prescription Opioid Abuse: Science, Public Health, and Policy*

Discussant

Sidney H. Schnoll, MD, PhD

Fellows Addresses (S): [Division 28 New Fellows Addresses]	8/12 Sat: 1:00 PM - 1:50 PM	Morial Convention Center Meeting Room 335
--	-----------------------------	--

Chair

Stephen J. Heishman, PhD

Participant/1stAuthor

Hendree E. Jones, PhD

*Title: Treating Pregnant Opioid-Dependent Patients: Experience From Controlled Trials*

Douglas B. Marlowe, PhD, JD

*Title: Experimental Research on Judicial Supervision in Drug Courts*

Jane B. Acri, PhD

*Title: Medication Development for Addictive Disorders: Recent Changes in Preclinical Evaluations*





**PROGRAM SUMMARY SHEET**  
**APA Annual Convention**

**DIVISION 28 PROGRAM SUMMARY SHEET**

EVENT, TITLE and PEOPLE	DAY/TIME	FACILITY/ROOM
Symposium (S): Agonist Pharmacotherapy for Stimulant Abuse and Dependence---A Viable Option?	8/13 Sun: 8:00 AM - 9:50 AM	Morial Convention Center Meeting Room 334

Chair

Craig R. Rush, PhD

Participant/1stAuthor

S.S. Negus, PhD

*Title: Agonist Medications for Stimulant Dependence: Preclinical Studies*

William W. Stoops, PhD

*Title: Agonist Pharmacotherapy for Stimulant Abuse and Dependence: Human Laboratory Studies*

Joy M. Schmitz, PhD

*Title: Clinical Utility of Agonist Pharmacotherapy for Treating Cocaine Dependence*

Discussant

Frank Vocci, PhD

Invited Symposium (S): Environmental Influences on Brain Development--- Implications for Intervention?	8/13 Sun: 10:00 AM - 11:50 AM	Morial Convention Center Meeting Room 341
--	-------------------------------	---

Cochair

Minda R. Lynch, PhD

Nicolette Borek, PhD

Participant/1stAuthor

Susan L. Andersen, PhD

*Title: Sensitive Periods and Early Effects of Stress*

Megan R. Gunnar, PhD

*Title: Bringing Basic Research on Early Experience and Stress Neurobiology to Bear on Preventive Intervention Research on Neglected and Maltreated Children*

Michael D. De Bellis, MD, MPH

*Title: Psychobiology of Maltreatment*

Linda C. Mayes, MD

*Title: Long-Term Impact of Prenatal Cocaine Exposure on Executive Control Functions*

**Total Number of Sessions = 17**



# EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY

EDITOR: NANCY K. MELLO, Ph.D.

MANAGING EDITOR: INGE M.  
KNUDSON, M.S.

ISSN: 1064-1297

PUBLISHED QUARTERLY BY THE  
AMERICAN PSYCHOLOGICAL  
ASSOCIATION

## Journal Description

*Experimental and Clinical Psychopharmacology* publishes advances in translational and interdisciplinary research on psychopharmacology and the treatment of drug abuse and comorbid psychiatric disorders. The scope of research in these areas continues to expand, and to benefit from collaborations across a broad range of disciplines, including behavioral science, brain imaging, genetics, neuroendocrinology, neuroscience, and pharmacology. One goal of the journal is to encourage increased attention to biologic factors that may influence both the pharmacodynamic and pharmacokinetic effects of drugs. Recent research has shown the impor-

tance of examining the effects of gender and menstrual/estrous cycle phase on the effects of abused drugs, as well as responses to medications for the treatment of drug abuse, mental illness, and the alleviation of pain.

The journal publishes original reports on the development and evaluation of new pharmacotherapies, the influence of genetics and hormones on responses to abused drugs and treatment medications, the pharmacological management of pain, and brain imaging studies of the neural correlates of drug effects. The journal will focus on clinical laboratory studies and controlled clinical medication trials as well as basic preclinical experiments on psychopharmacology. The journal also will include comprehensive and integrative reviews of advances in research on psychopharmacology. These reviews should provide a broad perspective on a particular area of research or trace the development of critical concepts and experimental approaches.

Each year, the journal will recognize young investigators who are recipients of the Young Psychopharmacologist Award or the Best Dissertation Award, as well as mid-career and senior scientists who receive the Brady-Schuster Award from APA Division 28, Psychopharmacology and Substance Abuse. Awardees will be invited to submit a review paper based on their award-winning research.

The journal may occasionally publish innovations in psychopharmacology that report a novel method, measure, or result. Commentary on the nature and implications of the innovation may be invited. The overall goal is to provide a forum for innovative clinical and preclinical research that advances our understanding of the behavioral and biological determinants of the effects of abused drugs and treatment medications.

**Web site address:** [www.apa.org/journals/pha/submission.html](http://www.apa.org/journals/pha/submission.html)

# Experimental and Clinical Psychopharmacology

[www.apa.org/journals/pha.html](http://www.apa.org/journals/pha.html)

May 2006

Volume 14  
Number 2

## Original Reports

- 99 Intravenously Cocaine Discrimination in Humans  
*Chris-Ellyn Johanson, Leslie H. Lundahl, Nancy Lockhart, and Howard Schubiner*
- 109 Assessment of Agonist and Antagonist Effects of Tramadol in Opioid-Dependent Humans  
*C. Patrick Carroll, Sharon L. Walsh, George E. Bigelow, Eric C. Strain, and Kenzie L. Preston*
- 121 Transdermal Nicotine-Induced Tobacco Abstinence Symptom Suppression: Nicotine Dose and Smokers' Gender  
*Sarah E. Evans, Melissa Blank, Cynthia Sams, Michael F. Weaver, and Thomas Eissenberg*

Copyright © 2006  
by the  
American  
Psychological  
Association

*Continued on page 13*



- 136 Discriminative-Stimulus, Self-Reported, Performance, and Cardiovascular Effects of Atomoxetine in Methylphenidate-Trained Humans  
*Joshua A. Lile, William W. Stoops, Todd M. Durell, Paul E. A. Glaser, and Craig R. Rush*
- 148 A Comparison Between Low-Magnitude Voucher and Buprenorphine Medication Contingencies in Promoting Abstinence From Opioids and Cocaine  
*Anke Groß, Lisa A. Marsch, Gary J. Badger, and Warren K. Bickel*
- 157 Methadone Maintenance Improves Cognitive Performance After Two Months of Treatment  
*Staci A. Gruber, Golfo K. Tzilos, Marisa M. Silveri, Mark Pollack, Perry F. Renshaw, Marc J. Kaufman, and Deborah A. Yurgelun-Todd*
- 165 Characterizing Nicotine Withdrawal in Pregnant Cigarette Smokers  
*Sarah H. Heil, Stephen T. Higgins, Joan A. Mongeon, Gary J. Badger, and Ira M. Bernstein*
- 171 The Use of Contingency Management to Reduce Cigarette Smoking Among College Students  
*Christopher J. Correia and Trisha A. Benson*
- 180 Interdose Interval Effects on the Development of Contextual Tolerance to Nicotine's Analgesic Effects in Rats (*Rattus norvegicus*)  
*Antonio Cepeda-Benito, Jose T. Reynoso, Kristina W. Davis, Agnes Susabda, Ian A. Mendez, and James H. Harraid*
- 190 Diazepam Impairs Behavioral Inhibition but Not Delay Discounting or Risk Taking in Healthy Adults  
*Ashley Acheson, Brady Reynolds, Jerry B. Richards, and Harriet de Wit*
- 199 The Effects of Naltrexone on Alcohol Consumption and Affect Reactivity to Daily Interpersonal Events Among Heavy Drinkers  
*Stephen Armeli, Richard Feinn, Howard Tennen, and Henry R. Kranzler*
- 209 Tonic and Phasic Processes in the Acute Effects of Alcohol  
*Christopher S. Martin, Carey D. Balaban, and Donald H. McBurney*
- 219 Relative Reinforcing Efficacy of Alcohol Among College Student Drinkers  
*James G. Murphy and James MacKillop*
- 228 Characterizing Alcohol Dependence: Transitions During Young and Middle Adulthood  
*Kristina M. Jackson, Susan E. O'Neill, and Kenneth J. Sher*
- 245 The Effects of Acquisition Training Schedule on Extinction and Reinstatement of Cocaine Self-Administration in Male Rats  
*Rodrigo Valles, Angelica Rocha, and Jack R. Nation*
- 254 Application of a Computational Decision Model to Examine Acute Drug Effects on Human Risk Taking  
*Scott D. Lane, Eldad Yechiam, and Jerome R. Busemeyer*
- 265 Analytic Complexities Associated With Group Therapy in Substance Abuse Treatment Research: Problems, Recommendations, and Future Directions  
*Antonio A. Morgan-Lopez and William Fals-Stewart*

## Other

- 264 American Psychological Association Subscription Claims Information  
227 E-Mail Notification of Your Latest Issue Online!  
274 Instructions to Authors  
147 Subscription Order Form



# STUDENTS: GET INVOLVED!

In between classes, research projects, and the many other duties graduate students typically face, professional involvement and service is one aspect that is easily overlooked. Professional involvement and service allows students to develop new skills that will be useful in their future careers, and it also provides of a forum for networking with colleagues. Following are a few suggestions on ways students can become more involved in Division 28, APA, or the field of psychopharmacology and substance abuse.

- **Join Division 28 and encourage your colleagues to join.** One of the most important ways that students can become more involved is to simply join Division 28. As a student affiliate of the Division, you will learn about opportunities for psychopharmacology and substance abuse students. To join, e-mail membership chair Dr. Joshua Lile (jalile2@uky.edu).
- **Communicate via the Division 28 Student listserv.** The new student listserv is up and running! The listserv was created for distribution of student-related announcements, questions, and concerns. If you have any information that would be of use to psychopharmacology and substance abuse students, please share it with us at [div28s@lists.apa.org](mailto:div28s@lists.apa.org). Similarly, the listserv provides a forum for students to obtain information from their peers. To join the listserv, e-mail student representative Jennifer Perry ([perry050@umn.edu](mailto:perry050@umn.edu)).
- **Contribute to the Division 28 Newsletter.** Psychopharmacology and Substance Abuse News is published tri-annually, and it serves

to keep Division 28 members informed about division activities. The newsletter also provides news and commentaries on any aspect of psychopharmacology and substance abuse. To submit materials for the newsletter, contact Dr. John Roll ([johnroll@wsu.edu](mailto:johnroll@wsu.edu)).

- **Attend the annual APA convention.** The annual APA convention is a great place to network with other APA and Division 28 members. This year's convention will feature several activities that may be of interest to psychopharmacology and substance abuse students. For example, there will be symposia on negotiating authorship credit and obtaining funding for graduate school and beyond, and there will also be several social opportunities for students to mingle with each other and their more senior colleagues. For more information on this year's APA convention, see [www.apa.org/convention06](http://www.apa.org/convention06) and watch for more information in upcoming Division 28 newsletters.
- **Get involved in APAGS.** The American Psychological Association of Graduate Students (APAGS) has numerous ways for students to get involved, such as volunteering at the annual convention or writing an article for the APAGS Web site. There are also opportunities for students to become involved in APAGS governance or advocacy. For more information, see [www.apa.org/apags/getinv](http://www.apa.org/apags/getinv).
- **Keep track of the SSC.** The APA Science Student Council (SSC) consists of nine science-oriented graduate students from different disciplines within psychology who

advise the APA Science Directorate on student-related issues. Congratulations to Kelly Dunn, a Division 28 student affiliate from the University of Vermont, for recently becoming elected to this board! To learn more about the SSC, including opportunities for involvement, see [www.apa.org/science/apasscweb.html](http://www.apa.org/science/apasscweb.html).

- **Become a peer reviewer.** A great way for graduate students to gain skills that they will use throughout their career is to get involved in the peer review process. Students typically become involved in this process by assisting in an advisor's review of a paper; however, students can also become involved in the peer review process by contacting a journal editor directly and requesting that they be included as an ad-hoc reviewer. Policies on student reviewing vary depending on the journal, so talk with your advisor or a journal editor to learn how more about opportunities for involvement.

I hope that these suggestions will encourage you to become more involved in Division 28, APA, and the field of psychopharmacology and substance abuse. Professional involvement will undoubtedly enhance your skill set, and it may allow you to develop new relationships with colleagues. Additionally, involvement in professional activities is a great way to strengthen and broaden your interests in psychopharmacology and substance abuse. I wish you the best in all your future professional involvement endeavors.

Sincerely,  
Jennifer L. Perry



---

**Research Associate/Research Scientist Position, Washington Institute for Mental Illness Research & Training, Washington State University-Spokane, position located in Olympia**

The Washington Institute for Mental Illness Research & Training (WIMIRT) at Washington State University Spokane (WSUS) is seeking candidates with demonstrated expertise in co-occurring disorders (mental health & chemical dependency) for a newly established position. The position is a full-time, annual appointment open to individuals at the postdoctoral through senior investigator level. More experienced applicants will be considered for a faculty position at the Research Associate/Research Scientist level. This position was created with the intent of establishing an ongoing program of policy-relevant co-occurring research. The position is currently funded through June 2007 with the expectation of continued support contingent upon satisfactory performance and availability of funds. The salary is competitive, includes excellent fringe benefits, and is commensurate with experience. Responsibilities include conducting policy-relevant evaluation and research that addresses issues of direct relevance to the state Mental Health Division (MHD) and the state Division of Alcohol and Substance Abuse (DASA). The successful candidate will also be expected to develop an externally funded research program. The position will have appointments at both WIMIRT, Eastern Branch, and at WSUS. Funding for this position is provided jointly by the MHD and DASA.

Required qualifications: Doctoral degree in one of the behavioral, biological, social, or health-related sciences with demonstrated expertise in the area of co-occurring mental health and substance abuse disorders. Preferred qualifications: Demonstrated ability to establish a vigorous, independent, externally funded research program and a scholarly publications record in co-occurring disorders. Demonstrated interest and experience in health sciences research including a history of working with large administrative data sets are also preferred qualifications.

WIMIRT is a partnership between the State Mental Health Division and the state's universities. The Eastern Branch is located in Spokane, Washington, and is affiliated with WSUS. WIMIRT's purpose is to improve collaboration between state government and state colleges and universities, and to conduct training and research that directly benefits mentally ill persons in Washington State. The research program of the Institute at WSU is currently funded by state contracts and by federal, private, and industry grants. There are five doctoral faculty members; approximately 10 additional faculty and staff are supported through grants and contracts.

The position is located in Olympia, Washington, in order to provide physical proximity to both the MHD and DASA. Olympia is the capital of Washington and is set on the southern shores of Puget Sound about 60 miles south of Seattle, Washington, and 110 miles north of Portland, Oregon. Olympia ranks as one of America's loveliest cities and is within a two-hour drive to Mount Rainier and ocean beaches.

Review of applications will begin July 1, 2006. Interested applicants should submit curriculum vitae, names and contact information of three references, two to three representative publications, and a two to three page statement of goals and interests to: John Roll, Ph.D., Director, WIMIRT. Chair, Search Committee. Washington Institute for Mental Illness Research & Training (Eastern Branch). PO Box 1495. Spokane, WA 99210-1495. 509-358-7612. WSU is an EEO/AA educator and employer.

---

**Two Open-Rank, Tenure-Track Faculty Positions, College of Public Health, University of Arkansas for Medical Sciences, Little Rock**

The UAMS College of Public Health invites applications for two tenure-track positions at the As-

stant, Associate, or Full Professor level. (1) The first will be a joint position between the Arkansas Division of Health (ADH) and the UAMS College of Public Health. This position will lead and oversee the ADH tobacco prevention and treatment programs and help determine the future direction of tobacco related services in the State (estimated budget of \$17 million). Arkansas is the only state continuing to devote its Master Settlement Agreement funding to health-related issues, a part of funds the ADH tobacco activities which bring Arkansas up to CDC recommended levels of funding. We seek applicants with strong leadership ability and demonstrated skills in program development and administration, as well as experience in tobacco cessation treatment and prevention. Applicants should also have research and teaching interests involving tobacco and/or nicotine. Physicians are encouraged to apply. (2) The second position is for a faculty member with interests in the economic, legal, and/or socio-cultural forces that affect tobacco policy, prevention, and treatment. Individuals with strong research expertise in primary tobacco prevention research or behavior, finance, decision analysis, health economics, and rural health related to tobacco dependence are encouraged to apply. Both positions would be expected to participate in the Center for Addiction Research at UAMS.

Applicants for both positions should have a doctoral degree in one of the relevant social, health, or management sciences. A strong record of research publications and extramural funding, or evidence of the ability to develop such a record, is also required. Experience in teaching at the graduate level and engaging in research translation and public service is also highly desirable. Successful applicants will become part of a recently-established but rapidly-growing college with a public mandate to conduct education and research supporting health improvement.

The newly accredited College of Public Health was created in 2001 with a portion of the state's tobacco settlement funds. The College enjoys close relationships with the state's health and human service agencies (particularly the ADH) and the UAMS Colleges of Medicine, Pharmacy, Nursing, and Health Related Professions. Opportunities for collaboration also exist with the new Clinton School of Public Service and with the business and law schools and other academic units within the University of Arkansas system. Salary and benefits are competitive and include a generous research incentive program.

Candidates should send a current CV, a letter describing areas of expertise, and a list of possible references to Warren K. Bickel, Ph.D. 4301 West Markham #820, Little Rock, AR 72205. E-mail: wbickel@uams.edu. Applications will be accepted until the positions are filled. UAMS is committed to equal opportunity, affirmative action, and the diversity of its faculty and staff. Women and minorities are strongly encouraged to apply.

---

**Postdoctoral Position, Department of Psychiatry, Miller School of Medicine, University of Miami, Florida**

A postdoctoral fellowship position is available immediately at the University of Miami Miller School of Medicine to study the behavioral and neurochemical effects of drugs of abuse. Current emphasis is on interactions between opioids and cocaine and other psychostimulants on behavior and neurochemistry. Studies include drug self-administration, locomotor activity, receptor binding, uptake, and second messenger function of dopamine, cannabinoid, nicotinic, and opioid receptors. Applicants should have a strong interest in learning to do neurochemical assays and in integrating behavioral and neurochemical studies. Experience with self-administration is desirable and experience with laboratory animals is essential.

Please contact: Sari Izenwasser, Ph.D. Department of Psychiatry (D-80). University of Miami Miller School of Medicine. 1400 NW 10th Ave, Room 704A. Miami, FL 33136. 305-243-2032. s.izenwasser@miami.edu.

---

**Postdoctoral Position, Department of Psychiatry, University of Pittsburgh, Pennsylvania**

A postdoctoral position in the behavioral pharmacology of nicotine in humans may be available in the laboratory of Dr. Kenneth A. Perkins at the University of Pittsburgh. This position is funded through NHLBI. Ongoing NIDA-supported projects focus on: 1) environmental modulation of nicotine responses and tobacco self-administration, 2) individual differences associated with sensitivity to nicotine, including gender, genetic, and personality factors. Applicants also interested in clinical research may become involved in smoking cessation studies. Interested candidates should send a CV and letter of interest to Dr. Perkins at the following address: Kenneth A. Perkins, Ph.D. Department of Psychiatry, University of Pittsburgh Medical Center. 3811 O'Hara Street. Pittsburgh, PA 15213. 412-246-5395. Fax 412-246-5390. perkinska@upmc.edu. myprofile.cos.com/perkinsk31

---

**Postdoctoral Position, Smoking Research Group, Department of Psychology, University of Pittsburgh, Pennsylvania**

The Smoking Research Group at the University of Pittsburgh (Saul Shiffman, Ph.D., Director) is seeking a postdoctoral fellow to serve as the project director and co-investigator on a newly-funded, multi-year project to study smoking patterns in "intermittent smokers"—people who smoke less than daily. The study focuses on stimulus control of smoking, using both Ecological Momentary Assessment and laboratory cue-reactivity methods, and will include a substantial African-American sample. The Project Director would be responsible for overseeing all aspects under the direction of the PI. Candidates should ideally have a doctorate in psychology or closely-related field. Prior experience in smoking research and project management are desirable, as is experience with EMA, cue-reactivity, or minority populations. The position has opportunities for pursuit of other research and for progression to a non-tenure stream research faculty position. The University of Pittsburgh has particular strength in Health Psychology and Behavioral Medicine, and Pittsburgh is a vibrant mid-size city with many cultural opportunities. The start date is August–November 2006. Interested candidates should send a CV and summary of experience and interests via e-mail to **Saul Shiffman, Ph.D.**, Director, Smoking Research Group, Department of Psychology, University of Pittsburgh, at shiffman@pitt.edu.

---

**Postdoctoral Position, Department of Psychiatry, University of Vermont, Burlington**

The University of Vermont announces the availability of three postdoctoral research fellowships in an internationally recognized center of excellence for the study of drug abuse. Fellows have opportunities for training in a wide range of epidemiological, human laboratory, and treatment-outcome research. Current openings are with Stephen Higgins (stephen.higgins@uvm.edu, 802-656-9614) in delineating behavioral and pharmacological processes central to understanding and effectively treating cocaine dependence as well as cigarette smoking among pregnant women, and John Hughes (john.hughes@uvm.edu, 802-656-9610) in clinical, laboratory, and epidemiology research on (1) gradual reduction with NRT as a method of smoking cessation and (2) understanding why smokers do not access free treatments for smoking cessation. Applicants must have completed doctoral training in psychology or a related discipline and be U.S. citizens or permanent residents. Salary is competitive commensurate with experience (PGY 1 to PGY 7) and supported by an NIDA/NIH Institutional Training Award.

For more details on the positions please contact the investigators directly at the e-mail addresses/phone numbers shown above. To apply



John M. Roll, Ph.D.  
 Director  
 Washington Institute for Mental Illness  
 Research and Training  
 Washington State University Spokane  
 PO Box 1495  
 Spokane, WA 99210-1495

please forward a curriculum vitae, statement of research interests, and three letters of reference to c/o Ms. Diana Cain, University of Vermont, Department of Psychiatry, 38 Fletcher Place, Burlington, VT 05401-1419. The University of Vermont is an affirmative action and equal opportunity employer.

**Postdoctoral Research Fellowships, Substance Abuse Research, Johns Hopkins University, Baltimore, Maryland**

Postdoctoral research fellowships in stimulating, productive program with excellent resources. Prepare as independent investigator.

Human Laboratory—behavioral and clinical pharmacology of abused drugs (abuse liability, self-administration, cognitive function, neuroimaging); anti-drug-abuse medi-

cations development. Opioids, cocaine, anxiolytics, alcohol, caffeine, nicotine.  
 Clinical Trials—testing medications, verbal and behavioral therapies (especially incentive/motivation-based), and combinations; psychiatric comorbidity research; addiction and pregnancy/women. Opioid, cocaine, tobacco, mixed/other dependencies.  
 Start Date: flexible.  
 Eligibility: citizen, permanent resident.  
 A broad range of backgrounds is appropriate—from clinical/counseling to experimental/neuroscience.  
 NIH stipend levels: \$35 - 51k+.  
 Contact George Bigelow, Roland Griffiths, or Maxine Stitzer; BPRU, Behavioral Biology Research Center; 5510 Nathan Shock Drive; Johns Hopkins Bayview Campus; Baltimore, Maryland 21224-6823; 410-550-0035; bigelow@jhmi.edu. See www.bpru.org.

Visit our new Web site:  
[www.apa.org/divisions/div28](http://www.apa.org/divisions/div28)

**DIVISION 28 EXECUTIVE COMMITTEE**

**ELECTED OFFICERS:**

President	Alan Budney
Past President	James Zacny
President-Elect	Suzette Evans
Council Representative	John Grabowski
Members-at-Large	Craig Rush Nancy Petry Kimberly Kirby

**APPOINTED OFFICERS:**

Secretary	Drake Morgan
Treasurer	Jane B. Acri
Newsletter Editor	John Roll
Divisional Awards	Anthony Liguori
Membership	Joshua Lile, jalile2@uky.edu
New Fellows	Stephen Heishman
Convention Program Chair	
2005	Diana Walker
2006	Stacey Sigmon

**INFORMATION OFFICERS:**

Archivist	Richard Foltin
Electronic Information	Ronald W. Wood

**COMMITTEE CHAIRS:**

Continuing Education	M. Marlyne Kilbey
----------------------	-------------------

**APPOINTED LIAISONS/MONITORS:**

Board of Scientific Affairs	Marilyn Carroll Ronald Wood
Board of Educational Affairs	M. Marlyne Kilbey
Liaison to Division 50	Linda Sobell
Women's Network Representative	Nancy Piotrowski
International Relations Committee	Mark Fillmore
Liaison to CARE	James Rowlett
Student Representative	Jennifer Perry
Liaison to Scientific Directorate	Conrad Wong
Liaison to Division 55	Mark Fillmore

